Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Vemurafenib and ipilimumab: new agents for metastatic melanoma.
Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260.
Am J Health Syst Pharm. 2013.
PMID: 23820456
Review.
Disadvantages of vemurafenib include the short duration of response; significant skin toxicities, including skin cancers and severe photosensitivity; the need for long-term daily administration; and the potential for drug interactions. ...
Disadvantages of vemurafenib include the short duration of response; significant skin toxicities, including skin cancers and severe photosen …
Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y, Simondsen K, Kolesar JM.
Zhang Y, et al. Among authors: kolesar jm.
Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585.
Am J Health Syst Pharm. 2012.
PMID: 22855103
Ongoing clinical trials with other aromatase inhibitors are underway to evaluate the benefits and long-term skeletal risks. CONCLUSION: Exemestane 25 mg daily taken for at least three years is a new option for the prevention of breast cancer in high-risk postmenopausal wom …
Ongoing clinical trials with other aromatase inhibitors are underway to evaluate the benefits and long-term skeletal risks. CONCLUSIO …
Item in Clipboard
Cite
Cite